Should FOLFOXIRI plus bevacizumab Be the standard first-line therapy in metastatic colorectal cancer?

Oncologist. 2015 Mar;20(3):236-8. doi: 10.1634/theoncologist.2014-0495. Epub 2015 Feb 6.

Abstract

The TRIBE trial compared the FOLFOXIRI regimen plus bevacizumab with FOLFIRI plus bevacizumab in patients with metastatic colorectal cancer. FOLFOXIRI plus bevacizumab is an acceptable therapeutic option, but the results of the TRIBE trial do not establish this regimen as the best treatment option for patients with metastatic colorectal cancer.

Publication types

  • Editorial

MeSH terms

  • Antibodies, Monoclonal, Humanized / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Bevacizumab
  • Camptothecin / analogs & derivatives*
  • Camptothecin / therapeutic use
  • Clinical Trials as Topic
  • Colorectal Neoplasms / drug therapy*
  • Colorectal Neoplasms / mortality
  • Colorectal Neoplasms / pathology
  • Fluorouracil / therapeutic use
  • Humans
  • Leucovorin / therapeutic use
  • Liver Neoplasms / drug therapy
  • Liver Neoplasms / secondary
  • Neoplasm Metastasis / drug therapy
  • Organoplatinum Compounds / therapeutic use

Substances

  • Antibodies, Monoclonal, Humanized
  • Organoplatinum Compounds
  • Bevacizumab
  • Leucovorin
  • Fluorouracil
  • Camptothecin

Supplementary concepts

  • FOLFOXIRI protocol